Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo

Figure 5

Downregulation of survivin by celecoxib and DMC correlates with increased apoptosis and reduced cell growth and survival. The three glioblastoma cell lines U251, T98G, and LN229 (A), or the two pancreatic carcinoma cell lines BxPc-3 and MIA PaCa-2 (B), were treated with 30 or 50 μM DMC or remained untreated for 48 hours. The effects on cell growth/survival and on cell death were determined by various assays. The panels labeled Number of Colonies display the results from a colony forming assay, where the number of surviving cells able to spawn a colony of newly grown cells was determined; in this assay, the colonies of adherent cells were stained and visualized with methylene blue two weeks after drug treatment and were counted. The panels labeled % Cell Growth and Survival show the results from MTT assays performed at the end of the 48 hour drug treatment period. The panels labeled % Apoptotic Cells present the percentage of cells undergoing apoptosis as revealed by the TUNEL assay after 48 hours of drug treatment. At the bottom of each series of panels in A and B, the level of survivin protein at the end of drug treatment is shown, as determined by Western blot analysis with specific antibodies. Western blots for actin are also shown (as a loading control).

Back to article page